References
- Gabriel EM, Jatoi I. Breast cancer chemoprevention. Expert Rev Anticancer Ther 2012, 12, 223–228.
- William WN Jr, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 2009, 8, 213–225.
- Bulun SE, Chen D, Moy I, Brooks DC, Zhao H. Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab 2012, 23, 83–89.
- Bidgoli SA, Eftekhari T, Sadeghipour R. Role of xenoestrogens and endogenous sources of estrogens on the occurrence of premenopausal breast cancer in Iran. Asian Pac J Cancer Prev 2011, 12, 2425–2430.
- Straume AH, Løvås K, Miletic H, Gravdal K, Lønning PE, Knappskog S. Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour. Eur J Endocrinol 2012, 166, 941–949.
- Muftuoglu Y, Mustata G. Aromatase inhibitors and antiepileptic drugs: a computational systems biology analysis. Reprod Biol Endocrinol 2011, 9, 92.
- Galeazzi R, Massaccesi L. Insight into the binding interactions of CYP450 aromatase inhibitors with their target enzyme: a combined molecular docking and molecular dynamics study. J Mol Model 2012, 18, 1153–1166.
- Narayana BL, Pran Kishore D, Balakumar C, Rao KV, Kaur R, Rao AR, Murthy JN, Ravikumar M. Molecular modeling evaluation of non-steroidal aromatase inhibitors. Chem Biol Drug Des 2012, 79, 674–682.
- Roy PP, Roy K. Molecular docking and QSAR studies of aromatase inhibitor androstenedione derivatives. J Pharm Pharmacol 2010, 62, 1717–1728.
- Dai Y, Wang Q, Zhang X, Jia S, Zheng H, Feng D, Yu P. Molecular docking and QSAR study on steroidal compounds as aromatase inhibitors. Eur J Med Chem 2010, 45, 5612–5620.
- Roy PP, Roy K. Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors. J Mol Model 2010, 16, 1597–1616.
- Geisler J. Differences between the non-steroidal aromatase inhibitors Anastrozole and letrozole–of clinical importance? Br J Cancer 2011, 104, 1059–1066.
- Woo LW, Purohit A, Potter BV. Development of steroid sulfatase inhibitors. Mol Cell Endocrinol 2011, 340, 175–185.
- Yadav MR, Sabale PM, Giridhar R, Zimmer C, Haupenthal J, Hartmann RW. Synthesis of some novel androstanes as potential aromatase inhibitors. Steroids 2011, 76, 464–470.
- Berman HM, Henrick K, Nakamura H, Markley J, Bourne PE, Westbrook J. Realism about PDB. Nat Biotechnol 2007, 25, 845–846.
- Magrane M, Consortium U. UniProt Knowledgebase: a hub of integrated protein data. Database (Oxford) 2011, 2011, bar009.
- Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 1997, 18, 2714–2723.
- Hendlich M, Rippmann F, Barnickel G. LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. J Mol Graph Model 1997, 15, 359–63. http://www.modelling.leeds.ac.uk/pocketfinder/
- Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. DrugBank 3.0: a comprehensive resource for ‘omics’ research on drugs. Nucleic Acids Res 2011, 39, D1035–D1041.
- Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006, 49, 3315–3321.
- Schuler LD, Daura X, van Gunsteren WF. An improved GROMOS96 force field for aliphatic hydrocarbons in the condensed phase. J Comp Chem 2011, 22, 1205–1218.
- Marvin n.n.n (5.6), 201n (2011), https://www.chemaxon.com/forum/ftopic977.html